180 215

Cited 1 times in

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma

Authors
 Jaekyung Cheon  ;  Hyeyeong Kim  ;  Han Sang Kim  ;  Chang Gon Kim  ;  Ilhwan Kim  ;  Beodeul Kang  ;  Chan Kim  ;  Sanghoon Jung  ;  Yeonjung Ha  ;  and Hong Jae Chon 
Citation
 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Vol.15 : 1-11, 2023-01 
Journal Title
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
ISSN
 1758-8340 
Issue Date
2023-01
Keywords
atezolizumab ; bevacizumab ; child–Pugh B ; hepatocellular carcinoma ; systemic treatment
Abstract
Background:Atezolizumab plus bevacizumab (Ate/Bev) demonstrated promising efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the phase III IMbrave150 trial. However, patients with Child–Pugh B HCC were excluded in the abovementioned prospective trial. Therefore, we aimed to investigate the efficacy and safety of Ate/Bev in patients with Child–Pugh B HCC.
Methods:This multicenter retrospective study included 36 patients with Child–Pugh B advanced HCC who received Ate/Bev at four cancer referral centers between May 2020 and August 2021. Comparative analyses were performed with an independent cohort of patients with Child–Pugh A HCC from the same registry (n = 133).
Results:All patients received Ate/Bev as first-line systemic treatment for advanced HCC. The objective response and disease control rates of patients in the Child–Pugh groups B and A were 11.1% and 58.3% and 34.6% and 76.7%, respectively. The median progression-free survival (PFS) and overall survival (OS) were 3.0 months [95% confidence interval (CI), 1.7–4.3) and 7.7 months (95% CI, 4.8–10.6) in the Child–Pugh B group, whereas the median PFS and OS were 9.6 months (95% CI, 5.1–14.2) and not reached (95% CI, not available) in the Child–Pugh A group, respectively. Compared to the Child–Pugh A group, grade 3–4 adverse events (AEs) were more common in the Child–Pugh B group (44.4% versus 15.8, p < 0.001), with the most frequent grade 3–4 AEs being gastrointestinal bleeding (n = 6, 16.7%), neutropenia (n = 5, 13.9%), and thrombocytopenia (n = 4, 11.1%).
Conclusions:In the Child–Pugh B subgroup of patients with advanced HCC, Ate/Bev treatment showed modest clinical activity. However, due to the increased frequency of serious AEs, careful evaluation of treatment response and AE management is required in this subgroup of patients.
Files in This Item:
T202301628.pdf Download
DOI
10.1177/17588359221148541
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Chang Gon(김창곤)
Kim, Han Sang(김한상) ORCID logo https://orcid.org/0000-0002-6504-9927
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193719
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links